National Institute for Health and Care Excellence

Handheld cluster headache device recommended by NICE

An electronic handheld device that can be used to prevent and treat cluster headaches in some patients has been recommended in draft guidance published by the National Institute for Health and Care Excellence.…

Reductions in antibiotics achievable if guidelines on prescribing duration observed, says NICE

Substantial reductions in antibiotic exposure could be achieved by ensuring that the duration of prescriptions fall in line with national guidance, the National Institute of Health and Care Excellence has said.…

MS drug approved by NICE after NHS renegotiates price

A new drug to treat some adults with multiple sclerosis is now being recommended for use by the National Institute for Health and Care Excellence after the NHS renegotiated a lower price with the manufacturer Roche.…

NICE publishes decision aid to help patients choose greener asthma inhalers

The National Institute for Health and Care Excellence has developed a new patient decision aid to help patients choose the best asthma inhaler for both them and the environment.…

Updated NICE guidance on lung cancer includes material from Clinical Pharmacist

Updated National Institute for Health and Care Excellence guidance on lung cancer diagnosis and management, published on 28 March 2019, includes two algorithms originally developed for Clinical Pharmacist.…

NICE proposes lowering threshold for blood pressure treatment

Thousands more people could be eligible for blood pressure treatment under new National Institute for Health and Care Excellence draft guidance.…

NICE rejects ‘promising’ new treatment for migraine

The first monoclonal antibody therapy for migraine prevention has not been recommended by the National Institute for Health and Care Excellence on the grounds that it is not cost effective.…

Third biological treatment for severe asthma approved by NICE

An injectable drug for patients who struggle to control their asthma with inhalers has been approved by the National Institute for Health and Care Excellence.…

Personalising treatment for type 2 diabetes: why is NICE so behind?

The National Institute for Health and Care Excellence’s rudimentary approach to managing diabetes needs to catch up with the available evidence and put patients centre stage.…

NICE must provide patient decision aids if the tools are to become part of routine practice

The National Institute for Health and Care Excellence’s (NICE) guideline NG5 — ‘Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes’ — sets recommendations around patient decision aids (PDAs) used in consultations in…